



IFW

Attorney Docket No.: 056291-5222

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Matti AHLQVIST

Confirmation No: 9593

Serial No: 10/561,170

Group: 1621

Filed: December 16, 2005

Examiner:

Entitled: POTASSIUM OR SODIUM SALT OF (-)-2-{[2-(4-HYDROXYPHENYL)ETHYL]THIO}-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENOXY}ETHYL)PHENYL]-PROPANOIC ACID AND THEIR USE IN MEDICINE

**SECOND REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, Randolph Building  
401 Dulaney Street  
Alexandria, VA 22314 – MAIL STOP MISSING PARTS

Sir:


Attached is a red marked-up copy of the Official Filing Receipt received in the above-referenced application. The title is incorrect, and should read:

POTASSIUM OR SODIUM SALT OF (-)-2-{[2-(4-HYDROXYPHENYL)ETHYL]THIO}-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENOXY}ETHYL)PHENYL]-PROPANOIC ACID AND THEIR USE IN MEDICINE

It is respectfully requested that this information be corrected by the Patent Office, and a new Filing Receipt issued. A copy of the executed Declaration is attached.

It is believed no fees are necessary with this filing; however, should any fees be deemed necessary, kindly charge such fee to the Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Respectfully submitted,

  
Donald J. Bird, Reg. No. 25,323

Date: April 30, 2007

Customer Number 009629

Morgan, Lewis & Bockius LLP  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
202.739.3000



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	TOT CLMS	IND CLMS
10/561,170	12/16/2005	1621	1260	056291-5222	10	1

CONFIRMATION NO. 9593

9629  
 MORGAN LEWIS & BOCKIUS LLP  
 1111 PENNSYLVANIA AVENUE NW  
 WASHINGTON, DC 20004

CORRECTED FILING RECEIPT



\*OC000000023365887\*

Date Mailed: 04/13/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Matti Ahlqvist, Molndal, SWEDEN;  
 Martin Hans Bohlin, Sodertalje, SWEDEN;

**Power of Attorney:** The patent practitioners associated with Customer Number **09629**.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB04/02595 06/16/2004

## Foreign Applications

UNITED KINGDOM 0314131.4 06/18/2003

**If Required, Foreign Filing License Granted:** 01/25/2007

**The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/561,170**

**Projected Publication Date:** 05/03/2007

**Non-Publication Request:** No

**Early Publication Request:** No

RECEIVED

APR 16 2007

MORGAN, LEWIS & BOCKIUS LLP

56291-5222  
**DOCKETED**  
 By PSC Date 4/16/07

**Title**

Potassium or sodium salt of (-)-2-[(2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid and their use in medicine

**Preliminary Class**

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

### LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



101075-1P US

### COMBINED DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled:

POTASSIUM OR SODIUM SALT OF (-)-2-((2-(4-HYDROXYPHENYL)ETHYL)THIO)-3-[4-(2-{4-((METHYLSULFONYL)OXY)PHENOXY)ETHYL]PHENYL]-PROPANOIC ACID AND THEIR USE IN MEDICINE

the specification of which:

is attached hereto.

**OR**

was filed on \_\_\_\_\_ with Express Mail No. \_\_\_\_\_ (Application Number not yet known).

**OR**

was filed on 16 June 2004 (16.06.2004) as United States Application Number or PCT International Application Number PCT/GB2004/002595 and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:

U.S. Serial No.	Filing Date	Status
-----------------	-------------	--------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Serial No.	Filing Date	Status
-----------------	-------------	--------

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
GB	0314131.4	18 June 2003 (18.06.2003)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No


I hereby appoint all registered practitioners associated with Customer Number 09629 to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to:

**Customer Number 09629**

Direct all telephone calls to DONALD J. BIRD, at telephone number (202) 739-5320.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: AHLQVIST, Matti  
 Inventor's Signature:   
 Residence Address: Mölndal, Sweden  
 Citizenship: SE  
 Post Office Address: AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden

Full Name of Inventor: BOHLIN, Martin, Hans  
 Inventor's Signature:   
 Residence Address: Södertälje, Sweden  
 Citizenship: SE  
 Post Office Address: AstraZeneca R&D Södertälje, SE-181 85 Södertälje, Sweden